Thymosin Alpha-1 and Long COVID Fatigue: What the Post-Viral Research Suggests

first, the regulatory part you have to know

Thymosin Alpha-1 is on the FDA's Category 2 list, which means US compounding pharmacies can't legally make it. That's been the rule since 2023. The FDA announced in February 2026 that they intend to move it back to Category 1, but as of this writing, the formal paperwork hasn't published. Until it does, it isn't legally prescribable in the US through any telehealth platform or 503A pharmacy. (Important note: Thymosin Alpha-1 is approved as a prescription medication in roughly 35 countries internationally, under brand names like Zadaxin, primarily for hepatitis B treatment. The US Category 2 status is specifically a US compounding-pharmacy regulatory issue, not a global one.) This article isn't a recommendation to use this peptide.

the reader this is for

You had COVID at some point, maybe early on in 2020 or 2021, maybe more recently. The acute illness wasn't catastrophic. You recovered from the cough and the fever. But the energy never quite came back. You're six months in. Or twelve. Or, for some readers, two or three years in.

What you have isn't really fatigue in the way people use the word casually. It's something more specific. You can't push through the way you used to. Pushing through makes it worse the next day. Your tolerance for exercise that used to be easy is gone. Your cognition is foggy in a way that's hard to describe to people who haven't had it. You've been told it's anxiety, you've been told it's deconditioning, you've been told to try CBT and graded exercise, and maybe you tried those, and they didn't really help, and sometimes they made things worse.

This is Long COVID, specifically the post-acute infection syndrome subtype that involves the kind of post-exertional malaise that ME/CFS researchers have been studying for decades. And somewhere in the rabbit hole of reading about it, you came across Thymosin Alpha-1.

what thymosin alpha-1 actually is

Thymosin Alpha-1 (sometimes shortened to Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland. The thymus is the immune-system organ where T-cells mature, and Thymosin Alpha-1 is one of several thymic hormones involved in regulating T-cell function.^[1]

It was first isolated in the 1970s. The synthetic version (also called thymalfasin) has been a prescribed medication in dozens of countries for decades, primarily as an immunomodulator for hepatitis B and C infections, but also studied in cancer therapy, immune deficiency states, and infectious diseases ranging from septic shock to viral pneumonia.

The mechanism is genuinely interesting from an immunology perspective. Thymosin Alpha-1 doesn't suppress the immune system or boost it generically. It appears to modulate immune function, particularly the balance between Th1 (cellular) and Th2 (humoral) immunity, and the activation state of NK cells, dendritic cells, and various T-cell subsets. The effect is essentially: make the immune system work more like a healthy immune system, especially when it's dysregulated.^[2]

This modulator framing (not stimulator, not suppressor) is part of why it's been studied across such a wide range of indications. In situations where the immune system is doing something useful but inefficiently, a regulating signal can shift the response toward a more effective pattern.

the long covid research signal

Most of the Long COVID research on Thymosin Alpha-1 came out of the 2020-2022 period, primarily from China and Italy where the peptide was already in clinical use for other indications.^[3]

The rough picture from this body of work:

Acute COVID-19 in hospitalized patients. Multiple studies during 2020 and 2021 reported that Thymosin Alpha-1 added to standard care appeared to improve outcomes in moderate-to-severe COVID-19, particularly in patients with measurable T-cell depletion. The Italian retrospective studies were among the better-documented.

The immune-dysregulation theory of Long COVID. Long COVID research has converged on a theory that the post-acute fatigue syndrome involves persistent immune dysregulation, possibly viral reservoir effects, possibly T-cell exhaustion, possibly autoimmune triggers initiated by the original infection. The exact mechanism is debated, but the consensus is that something is off in the immune signaling, not just in physical conditioning.^[4]

The bridge. If Long COVID is driven by immune dysregulation, and Thymosin Alpha-1 is a documented immune modulator that has clinical use in similar dysregulated states (hepatitis B, septic shock), then the mechanism reasoning suggests Tα1 might help. A 2023 paper in International Immunopharmacology applied this mechanism-bridge logic directly, reporting that Thymosin Alpha-1 restored immune balance in lymphocytes from patients with post-acute COVID symptoms.^[5]

The critique that has to be made: this body of work is interesting and mechanism-anchored but the controlled trial evidence specifically for Long COVID fatigue endpoints is limited. Most of it is observational, retrospective, or based on extrapolation from acute COVID and other immune-dysregulation contexts to the Long COVID specifically. A well-powered RCT of Thymosin Alpha-1 for Long COVID with standardized fatigue endpoints (DePaul symptom questionnaire, post-exertional malaise measures, CPET data) doesn't yet exist in the published literature.

why long covid is so hard to study and treat

Part of why the Thymosin Alpha-1 Long COVID story is incomplete is that Long COVID itself is hard to study in the way that produces clean trial results.

It's heterogeneous. Long COVID isn't one syndrome. There are at least three distinct subtypes that researchers have identified: (1) the post-exertional-malaise/ME-CFS-like subtype, (2) the dysautonomia subtype (often POTS-like), (3) the cognitive/brain-fog subtype. Different mechanisms likely drive different subtypes. A treatment that helps subtype 1 might not help subtype 2.

The fatigue measures are tricky. Self-reported fatigue scales are subjective. Objective measures (CPET, two-day exercise tests) are burdensome and not always practical. Post-exertional malaise is real but happens 24-48 hours after exertion, which complicates standard outcome measurement.

The placebo response is large. Long COVID research has consistently shown substantial placebo responses, partly because patients with chronic illness who enter trials are often already at improvement-trajectory baseline, and partly because attention and structured care produce real effects.

The natural course varies. Some people improve over a year or two. Some plateau. Some get worse with specific triggers. Any intervention has to outperform a natural trajectory that itself is highly variable.

These problems aren't insurmountable, but they mean the trials that would resolve the Thymosin Alpha-1 question definitively are hard to design and slow to complete. The current evidence picture is genuinely mid-development rather than mature.

the long covid alternatives worth knowing about

For context, here's what's actually being tried for Long COVID currently, with rough evidence levels.

Pacing and energy management. First-line for the post-exertional-malaise subtype specifically. Counterintuitive but evidence-supported. Avoiding the boom-bust cycle of pushing-then-crashing prevents the malaise pattern that worsens the condition over time.

Low-dose naltrexone (LDN). Off-label use for Long COVID has accumulated meaningful clinical experience and some emerging trial evidence. Mechanism involves immune modulation and microglial effects. Lower-risk intervention; widely available through compounding pharmacies.

Cardiopulmonary rehab (carefully). For the deconditioning component, not as a substitute for treating the post-exertional malaise. Graded exercise without respect to PEM has worsened outcomes for ME/CFS-like subtypes; the careful version that respects pacing has some role.

Treatment of dysautonomia (where present). Beta-blockers, ivabradine, fludrocortisone, salt and water loading. These address the POTS component when that's part of the picture.

Antihistamines. Some Long COVID research has implicated mast cell activation as part of the dysregulation. H1 and H2 antihistamines (cetirizine, famotidine) have shown some effect in a subset of patients.

Antivirals. Paxlovid and other antivirals are being studied for the viral-reservoir hypothesis of Long COVID. Trial evidence is still emerging.

Stellate ganglion block. A specific anesthetic intervention that's shown promise in some Long COVID patients, particularly for the autonomic/anxiety overlap subtypes.

Thymosin Alpha-1 isn't on this list because it's not currently legally accessible in the US, not because the mechanism reasoning doesn't have a place in the conversation.

why you can't legally get it right now

Thymosin Alpha-1 is on the FDA's Category 2 bulk drug substances list. US 503A compounding pharmacies can't legally make it for prescription. This is the case even though the peptide is approved as a prescription medication in roughly 35 countries. The FDA's Category 2 status is specifically about US compounding regulation, not about the peptide's general safety or efficacy profile.

The February 2026 FDA reclassification announcement included Thymosin Alpha-1 in the cohort of peptides intended to move back to Category 1. As of this writing, the formal paperwork hasn't published. When it does, the legitimate compounding supply opens back up.

For more on the regulatory framework, see the current state of peptide legality.

The alternatives that don't require waiting for the reclassification:

International prescription. The peptide is legally prescribed in many countries (China, Italy, parts of South America, parts of Asia). Patients with international relationships sometimes obtain prescriptions through that route, though importation regulations and quality control vary.

Research-chemical gray market. Available through the usual research-chemical websites. The standard set of risks applies: unverifiable sourcing, contamination potential, no provider relationship if something goes wrong. We're not pointing you there.

Clinical trials. A handful of trials of Thymosin Alpha-1 for Long COVID may be in development. ClinicalTrials.gov is the search resource. If you fit eligibility criteria for an active trial, that's the legitimate access path.

what to do in the meantime if you have long covid

If you're reading this because you're in the Long COVID rabbit hole and Thymosin Alpha-1 caught your attention, the honest path forward is parallel rather than sequential.

Pursue what's actually legally and clinically available. The Long COVID specialist landscape has grown significantly since 2020. Major academic centers have Long COVID clinics. Some of these are seriously engaged with the post-viral immune-dysregulation framing and use the available evidence-based interventions thoughtfully. Find one that takes ME/CFS-pattern Long COVID seriously, not one that defaults to it's anxiety, here's a CBT referral.

Watch for the reclassification. If Thymosin Alpha-1 moves back to Category 1, the conversation about whether it makes sense for your specific situation becomes a real one to have with a clinician, with proper supply chain and dose oversight.

Be skeptical of the gray-market path. The cost-benefit math here is bad for chronic illness. You're already in a condition where your immune system is dysregulated, you have less margin for the contamination or impurity risks that gray-market sources carry. The provider-less approach is a bigger risk for this population than for healthier biohacker users of peptides for performance optimization.

Track the research. The Long COVID research landscape is moving. Trials are accumulating. The immune-dysregulation theory is consolidating. The therapeutic options will likely expand in the next 2-3 years as the underlying biology gets clarified.

For more on the kinds of immune-modulating peptide work being studied, see our broader piece on where the peptide therapy landscape currently sits.

the summary

Thymosin Alpha-1 has decades of clinical experience internationally as an immune modulator. The mechanism reasoning for why it might help with the immune-dysregulation that appears to drive at least one major subtype of Long COVID is genuine. Early observational and small-trial evidence from the COVID and Long COVID period is suggestive but not conclusive.

It's also currently illegal to compound in the US, which means the path to using it legitimately is either international prescription (with its own complications), clinical trial enrollment, or waiting for the FDA reclassification.

For someone living with Long COVID right now, the actionable path is pursuing what's actually available: competent Long COVID clinical care, the off-label interventions that have current evidence (LDN, antihistamines, careful pacing, dysautonomia management where relevant), and clinical trial participation if eligibility fits. The Thymosin Alpha-1 conversation is one to track and potentially have in a few months or years when the regulatory and trial situations clarify, not one to act on through gray-market channels in the current state of unknowns.

The condition is real. The science is moving. The intervention you're reading about isn't accessible legitimately in the US today. All three of those things are true at the same time.